Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Bookmark and Share
Published: 25 Apr 2018
Views: 4269
Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Dr Galbraith speaks with ecancer at AACR 2018 about a novel CDK9 inhibitor for diffuse large B cell lymphoma (DLBCL).

She discusses the mechanism of action of the investigatory treatment, and its effectiveness in combination with other treatment types to deliver targeted damage, growth control and cell death in tumours.

Clinical trials are ongoing.